Nesiritide (Natrecor)
Customize your policy alerts
Sign up for Aetna Policy 0709 alerts
Get alerted when Policy 0709 changes without checking for updates manually.
Monitor payer policy activity
Defines Aetna's medical necessity, investigational exclusions, and coding guidance for nesiritide (Natrecor) primarily for acute decompensated congestive heart failure and related settings; applies to Aetna members and providers submitting claims.
No material clinical or coverage changes in this revision.
Coverage Criteria for Nesiritide (Natrecor)
inv-01: Initial use — Acute management
Covered when ALL of the following are met:
Per policy medical necessity statement
Policy limits use to acutely decompensated patients; outpatient serial infusions are considered experimental/investigational
Per FDA labeling and policy guidance
inv-02: Coverage stance for acute decompensated heart failure
Covered only in selected patients when ALL of the following are met:
Support with clinical documentation linking to covered ICD-10 codes
Document prior therapies and responses; attempt other vasodilators/diuretics prior to nesiritide
Recommended prior to routine use
inv-03: Peri-operative cardiovascular surgery / renal protection
Use for peri-operative renal protection is investigational/limited evidence and may be considered only in research or select high-risk settings when documentation supports anticipated benefit:
Insufficient evidence to support routine peri-operative use
Document informed decision‑making and anticipated benefit
inv-04: Low-dose nesiritide for acute HF with renal dysfunction (ROSE trial findings)
Not supported for routine addition to diuretic therapy to enhance decongestion or preserve renal function:
Do not use routinely for this purpose
The policy excludes use of nesiritide for intermittent infusion in persons who are not acutely decompensated and for scheduled repetitive use (for example outpatient “tune‑up” infusions). The policy also lists use to enhance diuresis, to improve renal function, for prophylactic prevention of acute kidney injury, as adjuvant therapy following cardiac surgery (eg, after Fontan surgery), and other non‑label indications as experimental/investigational and excluded from coverage.
Meta-analyses and expert reviews cited in the policy support restricting nesiritide to hospitalized patients with acutely decompensated CHF, and therefore these outpatient or serial infusion applications are not supported by evidence of clinical benefit.
Nesiritide is contraindicated in persons with hypersensitivity to any of its components. Per the FDA‑approved labeling and the policy, it should not be used as primary therapy for cardiogenic shock or in patients with a systolic blood pressure < 90 mm Hg.
Use in these settings may lead to denial of coverage and carries potential for clinical harm (eg, worsening hypotension); documentation of contraindications should be reviewed prior to authorization.
The policy states that routine outpatient or broad population use of nesiritide for acute heart failure is not recommended. Evidence from large trials and guideline reviews found only modest, inconsistent symptomatic benefit and raised safety concerns, so nesiritide should be reserved for selected hospitalized patients rather than used routinely across the general heart‑failure population.
Guidance highlighted in the policy recommends attempting standard vasodilators and/or diuretics before considering nesiritide and involving subspecialty consultation when use is contemplated.
Clinical Policy Bulletins are developed to assist in administering plan benefits and are informational. They contain a general description of plan coverage considerations but do not constitute a contract or guarantee of benefits. Treating providers remain responsible for medical advice and treatment decisions; policies may be updated and are subject to change.
Serial outpatient or intermittent nesiritide infusions for patients with chronic or stage C/D heart failure have not demonstrated clinical benefit and are not medically necessary. The FUSION II trial and related studies showed no reduction in death or hospitalizations with scheduled outpatient infusions, and the policy therefore does not support routine outpatient infusion programs.
Outpatient “tune‑up” use (eg, weekly 4–8 hour infusions) for chronic decompensated HF is specifically identified as unsupported and considered experimental/investigational when not part of an approved trial.
Empiric peri‑operative administration of nesiritide to improve early postoperative outcomes (for example, after Fontan surgery) is not supported by the evidence. A randomized trial comparing peri‑operative nesiritide, milrinone, and placebo after Fontan found no significant improvement in days alive and out of hospital or other early clinical outcomes with nesiritide.
Accordingly, routine empiric peri‑operative use for early postoperative benefit is considered experimental/investigational and is not covered outside of research or clearly documented, exceptional circumstances.
Coding and Duration Guidance
Provider Actions, Prior Authorization, and Documentation
Prior Authorization for J2325 — Document Indication
Prior authorization required for nesiritide (HCPCS J2325) when used for acute decompensated congestive heart failure. Documentation must support the indication (acute decompensated CHF with dyspnea at rest or with minimal activity) and link to covered ICD-10 codes.
- Prior authorization required for J2325 when selection criteria are met.
- Medical record must document acute decompensated CHF with dyspnea at rest or with minimal activity.
Prioritize Other Therapies Before Nesiritide
Reserve nesiritide for patients who remain volume overloaded despite aggressive diuresis and/or vasodilator therapy. Use should be considered only after other standard therapies have been attempted.
- Attempt aggressive diuretics and vasodilators before nesiritide.
- Consider subspecialty (cardiology) consultation when using nesiritide.
Consider Alternatives Before Nesiritide
Providers should consider alternative treatments (diuretics, vasodilators) and the availability of alternatives prior to using nesiritide. Nesiritide may be considered when alternatives are ineffective, not tolerated, or contraindicated.
- Consider nitroglycerin, other vasodilators, and diuretics first.
- Document prior therapy attempts and reasons nesiritide is being selected.
Experimental/Investigational Uses — Not Covered
Use of nesiritide outside the acute management of acutely decompensated CHF with dyspnea at rest or with minimal activity (for example, intermittent outpatient infusions, scheduled repetitive use, enhancement of diuresis, improvement of renal function, prophylactic use to prevent acute kidney injury, adjuvant post‑cardiac surgery) is considered experimental/investigational and is not covered.
- Intermittent outpatient infusions and scheduled repetitive use — experimental/investigational.
- Use to enhance diuresis or improve renal function — experimental/investigational.
- Peri-operative administration and subcutaneous BNP — experimental/investigational.
Contraindications — Denial Risk if Used Inappropriately
Nesiritide is contraindicated as primary therapy in cardiogenic shock and should not be used in patients with systolic blood pressure < 90 mm Hg. Hypersensitivity to components of nesiritide is a contraindication. Use in these situations may result in denial.
- Do not use as primary therapy for cardiogenic shock.
- Do not administer if systolic BP < 90 mm Hg.
- Document absence of contraindications in the medical record.
Restricted Routine Use — Limit to Selected Patients
Routine use of nesiritide in broad populations of patients with acute heart failure is not recommended. Limit use to selected patients meeting policy criteria and document rationale when used outside typical settings.
- Not recommended for routine or standard use in all patients with acute HF.
- Reserve for selected patients meeting clinical criteria and after other therapies tried.
Required Clinical Documentation
Medical records must clearly support the diagnosis of acute decompensated CHF with dyspnea at rest or with minimal activity and include documentation of prior therapy attempts (diuretics, vasodilators), clinical findings of volume overload if present, and linkage to appropriate ICD-10 codes.
- Document dyspnea at rest or with minimal activity and acute decompensation.
- Record prior diuretic/vasodilator therapy and response or intolerance.
- Include covered ICD-10 codes (e.g., I50.21, I50.23, I50.31, I50.33, I50.41, I50.43).
This Section Contains Policy History and Administrative Notices
Policy history, review dates, and administrative notices are provided in the policy header and history section. Providers should refer to the policy history for the last review date, effective date, and next review date.
- Effective: 08/26/2005
- Last Review: 09/20/2023
- Next Review: 08/08/2028
Step Therapy Status Note — No Step Therapy Requirements Stated
No formal step therapy requirements are specified in this policy for nesiritide; however, clinical guidance and external guidelines recommend attempting vasodilators and/or diuretics other than nesiritide prior to trialing nesiritide.
- Policy does not impose an explicit step therapy program.
- Clinical practice guidance recommends trying alternatives before nesiritide.
Background and Rationale
Nesiritide is a recombinant form of human B‑type natriuretic peptide (Natrecor) approved by the FDA for intravenous use to provide early relief of dyspnea in patients hospitalized with acutely decompensated congestive heart failure who have dyspnea at rest or with minimal activity. The labeled regimen (commonly referenced in the policy) includes a 2 µg/kg bolus followed by a 0.01 µg/kg/min infusion for up to 48 hours.
Clinical trial data summarized in the policy show nesiritide can modestly improve shortness of breath but have not demonstrated improvements in mortality or hospital length of stay, and safety signals (including possible renal effects and hypotension) prompted label revisions and expert recommendations to limit use to hospitalized acutely decompensated patients.
Definitions and Key Terms
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.